Close Menu

NEW YORK (GenomeWeb) – British research tools maker Abcam announced today that it has signed an agreement to acquire Cambridge, Mass.-based Firefly BioWorks for £18.5 million ($28 million) in cash.

Founded in 2010, Firefly has developed a multiplex assay biomarker-detection platform based on a proprietary technology called optical liquid stamping, which combines photolithography with microfluidics. The company's first products allow for the detection of cellular and circulating microRNAs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.